


AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound having the formula I:



(I)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted C₁-C₆-alkyl,
- (2) substituted or unsubstituted C₂-C₆-alkenyl,
- (3) substituted or unsubstituted C₂-C₆-alkynyl,
[[(4)]] (1) substituted or unsubstituted aryl,
[[(5)]] (2) substituted or unsubstituted heterocyclyl, and
[[(6)]] (3) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R^{1x})-,
- (3) -(CH₂)_m-C(R^{2x}, R^{3x})-N(R^{1x})-,
- (4) -O-,
- (5) -S-,
- (6) -SO-,
- (7) -SO₂-,
- (8) -C(R^{2x}, R^{3x})-, and
- (9)
—N—C₆H₃N—,

wherein R^{1x}, R^{2x}, and R^{3x} are selected from the group consisting of

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (a) H,
- (b) substituted or unsubstituted C₁-C₆-alkyl,
- (c) substituted or unsubstituted C₂-C₆-alkenyl,
- (d) substituted or unsubstituted C₂-C₆-alkynyl,
- (e) substituted or unsubstituted aryl,
- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R₁ is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOH,
- (4) halo,
- (5) -OR^{1t}, and
- (6) -NHR^{1t},

wherein R^{1t} is H or C₁-C₆-alkyl;


R₂ is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and
- (3) ~~substituted or unsubstituted heterocyclyl; and~~

W is selected from the group consisting of

(1) ~~substituted or unsubstituted C₁-C₆-alkyl,~~

[(2)] (1) -N(R^{1w}, R^{2w}), and



wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) H,
- (b) ~~substituted or unsubstituted C₁-C₆-alkyl,~~

LAW OFFICES OF
 CHRISTENSEN OCONNOR JOHNSON KINDNESS^{PLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100

[[(c)]] (a) substituted or unsubstituted aryl,
[[(d)]] (b) substituted or unsubstituted heterocyclyl, and
[[(e)]] (c) substituted or unsubstituted heteroaryl,
wherein R^{1w} and R^{2w} are not both H;

Z is selected from the group consisting of

- (a) -O-,
- (b) -NR^z-,
- (c) -S-,
- (d) -SO-,
- (e) -SO₂-, and
- (f) -CH₂-,

wherein R^z is H or substituted or unsubstituted alkyl group; and

R^{4w} is selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted C₁-C₆-alkyl,
- (c) -COOR^{5w},
- (d) -CONH₂,
- (e) -OR^{5w}, and
- (f) -NHR^{5w},

wherein R^{5w} is H or C₁-C₆-alkyl; and r is 0, 1, or 2;

~~with the proviso that when X is O, then Y is substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heteroaryl;~~

~~with the proviso that when W is morpholine, thiomorpholine, 1-oxide thiomorpholine, 1,1-dioxide morpholine, piperazine, or N-substituted piperazine, R₂ is morpholine, thiomorpholine, 1-oxide thiomorpholine, 1,1-dioxide thiomorpholine, piperazine, or N-[acetyl(alkanoyl of 1 to 3 carbon atoms)]piperazine, and X is NH, then Y is not hydrogen, alkyl of 1 to 3 carbon atoms, cyclohexyl, phenyl, chlorophenyl, carboxyphenyl, carbomethoxyphenyl, or pyridyl;~~

~~with the proviso that when W is morpholine, thiomorpholine, 1-oxide thiomorpholine, 1,1-dioxide morpholine, piperazine, or N-substituted piperazine, R₂ is morpholine, thiomorpholine, 1-oxide thiomorpholine, 1,1-dioxide thiomorpholine, piperazine, or N-[acetyl(alkanoyl of 1 to 3 carbon atoms)]piperazine, and X is a direct link, then Y is not phenyl, substituted or unsubstituted C₁-C₆ alkyl, or 1-oxidothiomorpholine; and~~

~~with the proviso that when R₂ is phenyl independently substituted with one to five substituents selected from hydrogen, cycloalkyl, heterocycloalkyl, halo, nitro, amino, sulphonamido, or alkylsulphonylamino, R₁ is hydrogen, haloalkyl, alkyl, or halo, and X is NR^{1x}, then Y is substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocyclyl.~~

2. (Currently amended) The compound of claim 1, wherein

Y is selected from the group consisting of


- (1) ~~substituted or unsubstituted C₁-C₆ alkyl,~~
- [(2)] (1) substituted or unsubstituted aryl,
- [(3)] (2) substituted or unsubstituted heterocyclyl, and
- [(4)] (3) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R^{1x})-,
- (3) -(CH₂)_m-C(R^{2x}, R^{3x})-N(R^{1x})-, and
- (4) ,

wherein R^{1x}, R^{2x}, R^{3x} are independently H or substituted or unsubstituted C₁-C₆-alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR^{2z}-, wherein R^{4w} is H or substituted or unsubstituted C₁-C₆-alkyl.


LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

3. (Original) The compound of claim 1, wherein

Y is selected from the group consisting of


- (1) substituted or unsubstituted heterocyclyl,
- (2) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) $-N(R^{1x})-$,
- (3) $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$, and
- (4) 

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted C₁-C₆-alkyl; and

W is selected from the group consisting of




wherein Z is -O- or -NR^z-, wherein R^{4w} is H or substituted or unsubstituted C₁-C₆-alkyl.

4. (Original) The compound of claim 1, wherein


Y is substituted or unsubstituted aryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) $-N(R^{1x})-$,
- (3) $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$, and
- (4) 

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted C₁-C₆-alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR^z, wherein R^{4w} is H or substituted or unsubstituted C₁-C₆-alkyl.

5. (Currently amended) The compound of claim 1, wherein


~~Y is substituted or unsubstituted alkyl;~~

X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R^{1x})-,
- (3) -(CH₂)_m-C(R^{2x}, R^{3x})-N(R^{1x})-, and
- (4) ,

wherein R^{1x}, R^{2x}, R^{3x} are independently H or substituted or unsubstituted C₁-C₆-alkyl; and

W is selected from the group consisting of



wherein Z is -O- or -NR^z, wherein R^{4w} is H or substituted or unsubstituted C₁-C₆-alkyl.

6. (Original) The compound of claim 1, wherein

Y is selected from the group consisting of


- (1) substituted or unsubstituted heterocyclyl,
- (2) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) -N(R^{1x})-,

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100


(3) $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$, and



wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted C_1-C_6 -alkyl;

R_2 is substituted or unsubstituted aryl; and

W is



wherein Z is -O- or -NH-.

7. (Original) The compound of claim 1, wherein


Y is substituted or unsubstituted aryl;

X is selected from the group consisting of

(1) a direct link,

(2) $-N(R^{1x})-$,


(3) $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$, and



wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted C_1-C_6 -alkyl;

R_2 is substituted or unsubstituted aryl; and

W is



wherein Z is -O- or -NH-.

8. (Currently amended) The compound of claim 1, wherein

Y is substituted or unsubstituted alkyl;

X is selected from the group consisting of


LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (1) a direct link,
- (2) $-\text{N}(\text{R}^{1x})-$,
- (3) $-(\text{CH}_2)_m-\text{C}(\text{R}^{2x}, \text{R}^{3x})-\text{N}(\text{R}^{1x})-$, and
- (4) ,

wherein R^{1x} , R^{2x} , R^{3x} are independently H or substituted or unsubstituted $\text{C}_1\text{-C}_6$ -alkyl;


R_2 is substituted or unsubstituted aryl; and

W is



wherein Z is -O- or -NH-.

9. (Currently amended) The compound of claim 1, having the formula II:



(II)

wherein Y is selected from the group consisting of


- (1) ~~substituted or unsubstituted $\text{C}_1\text{-C}_6$ -alkyl~~,
- [(2)] (1) substituted or unsubstituted aryl,
- [(3)] (2) substituted or unsubstituted heterocyclyl, and
- [(4)] (3) substituted or unsubstituted heteroaryl; and

X is selected from the group consisting of


- (1) a direct link,
- (2) $-\text{N}(\text{R}^{1x})-$,

LAW OFFICES OF
 CHRISTENSEN OCONNOR JOHNSON KINDNESS^{PLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100

(3) $-(CH_2)_m-C(R^{2x}, R^{3x})-N(R^{1x})-$, and




10. (Original) The compound of claim 1, having the formula II:



(II)


wherein Y and X, taken together, are selected from the group consisting of

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100




LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

11. (Original) The compound of claim 1, having the formula II:




(II)

wherein Y and X, taken together, are selected from the group consisting of




LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

12. (Original) The compound of claim 1, having the formula II:




(II)

wherein, Y and X, taken together, are selected from the group consisting of



13. (Currently amended) The compound of claim 1, having the formula III:




(III)

wherein R₃, R₄, R₅, R₆ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOR^{1t},
- (4) ~~-COONH₂ -CONH₂~~,
- (5) -OR^{1t}, and
- (6) -NHR^{1t}.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

14. (Currently amended) The compound of claim 1, having the formula IV:




(IV)

wherein R₃, R₄, R₅, R₆ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOR^{1t},
- (4) ~~-COONH₂ -CONH₂~~
- (5) -OR^{1t}, and
- (6) -NHR^{1t}.

15. (Currently amended) The compound of claim 1, having the formula V:



(V)

wherein R₃, R₄, R₅, R₆ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOR^{1t},
- (4) ~~-COONH₂ -CONH₂~~
- (5) -OR^{1t}, and

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

(6) $-\text{NHR}^{1t}$; and

R^{2a} and R^{2b} are selected from the group consisting of


- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) halo,
- (4) $-(\text{CH}_2)_q\text{-N}(\text{R}^{2c}, \text{R}^{2d})$,
- (5) $-(\text{CH}_2)_q\text{-N}(\text{R}^{2c}, \text{R}^{2d})\text{COR}^{2e}$,
- (6) $-(\text{CH}_2)_q\text{-OR}^{2e}$,
- (7) $-(\text{CH}_2)_q\text{-OCOR}^{2e}$,
- (8) $-(\text{CH}_2)_q\text{-OCOOR}^{2e}$,
- (9) $-(\text{CH}_2)_q\text{-COOR}^{2e}$,
- (10) $-(\text{CH}_2)_q\text{-CONR}^{2c}$,
- (11) $-\text{CN}$,
- (12) $-\text{NO}_2$,
- (13) $-\text{SO}_2\text{NH}_2$,
- (14) $-\text{NHSO}_2\text{CH}_3$, and
- (15) $-\text{SO}_2\text{R}^{2f}$,

wherein R^{2c} , R^{2d} , R^{2e} , and R^{2f} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted phenyl; and

q is 0, 1, 2, 3, or 4.


16. (Original) The compound of claim 1, having the formula VI:



(VI)


LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

wherein R₂ is selected from the group consisting of



LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

17. (Currently amended) The compound of claim 1, having the formula VII:




(VII)

wherein R₇, R₈, R₉, and R₁₀ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOR^{1t},
- (4) ~~-COONH₂ -CONH₂~~,
- (5) -OR^{1t}, and
- (6) -NHR^{1t}.

18. (Original) The compound of claim 1, having the formula VIII:




(VIII)

wherein R₇, R₈, R₉, R₁₀ are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOR^{1t},
- (4) -CONH₂,
- (5) -OR^{1t}, and
- (6) -NHR^{1t}.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

19. (Original) The compound of claim 1, having the formula IX:



wherein R^{1a} and R^{1b} are selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) halo,
- (4) -(CH₂)_q-N(R^{2c}, R^{2d}),
- (5) -(CH₂)_q-N(R^{2c}, R^{2d})COR^{2e},
- (6) -(CH₂)_q-OR^{2e},
- (7) -(CH₂)_q-OCOR^{2e},
- (8) -(CH₂)_q-OCOOR^{2e},
- (9) -(CH₂)_q-COOR^{2e},
- (10) -(CH₂)_q-CONR^{2c},
- (11) -CN,
- (12) -NO₂,
- (13) -SO₂NH₂,
- (14) -NHSO₂CH₃, and
- (15) -SO₂R^{2f},

wherein R^{2c}, R^{2d}, R^{2e}, and R^{2f} are selected from the group consisting of


- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted phenyl; and

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

wherein R₇ is selected from the group consisting of


- (1) H,
- (2) substituted or unsubstituted C₁-C₆-alkyl,
- (3) -COOR^{1t},
- (4) -CONH₂,
- (5) -OR^{1t}, and
- (6) -NHR^{1t}.

20. (Original) The compound of claim 1, having the formula X:




wherein R₂ is selected from the group consisting of

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



LAW OFFICES OF
 CHRISTENSEN OCONNOR JOHNSON KINDNESS PLLC
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100


21. (Original) The compound of claim 1, having the formula XI:



(XI)

wherein R^{2g} is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) -CONHR^{2h},
- (4) -CON(R^{2h})-(CH₂)₂₋₃-N(R^{2h}, R²ⁱ),
- (5) -COR^{2j},
- (6) -CO₂R^{2j},
- (7) -COC₁-C₆-alkyl-CO₂H,
- (8) -CH₂-OC(=O)R²ⁱ,
- (9) -CH₂-OC(=O)NHCHR²ⁱCO₂R^{2j},
- (10) -P(=O)(OR^{2k}, OR^{2p}),




wherein R^{2h}, R²ⁱ, R^{2j}, R^{2k}, and R^{2p} are selected from the group consisting of

- (a) H,

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted aryl.


22. (Original) The compound of claim 1, having the formula XII:




(XII)

wherein R^{2g} is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted alkyl,
- (3) -CONHR^{2h},
- (4) -CON(R^{2h})-(CH₂)₂₋₃-N(R^{2h}, R²ⁱ),
- (5) -COR^{2j},
- (6) -CO₂R^{2j},
- (7) -COCl-C₆-alkyl-CO₂H,
- (8) -CH₂-OC(=O)R²ⁱ,
- (9) -CH₂-OC(=O)NHCHR²ⁱCO₂R^{2j},
- (10) -P(=O)(OR^{2k}, OR^{2p}),



(11) , and




(12) ,

LAW OFFICES OF
 CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
 1420 Fifth Avenue
 Suite 2800
 Seattle, Washington 98101
 206.682.8100

wherein R^{2h}, R²ⁱ, R^{2j}, R^{2k}, and R^{2p} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted alkyl, and
- (c) substituted or unsubstituted aryl.

23. (Currently amended) A composition, comprising a pharmaceutically acceptable carrier and an amount of a compound of Claim 1 effective to inhibit phosphatidylinositol (PI) 3-kinase activity in a human or animal subject when administered thereto, ~~wherein the compound has the formula I:~~



(I)

~~or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof,~~
~~wherein~~


~~Y is selected from the group consisting of~~

- (1) ~~substituted or unsubstituted C₁-C₆-alkyl,~~
- (2) ~~substituted or unsubstituted C₂-C₆-alkenyl,~~
- (3) ~~substituted or unsubstituted C₂-C₆-alkynyl,~~
- (4) ~~substituted or unsubstituted aryl,~~
- (5) ~~substituted or unsubstituted heterocyclyl, and~~
- (6) ~~substituted or unsubstituted heteroaryl;~~

~~X is selected from the group consisting of~~

- (1) ~~a direct link,~~
- (2) ~~N(R^{1*}),~~
- (3) ~~(CH₂)_m-C(R^{2*}, R^{3*})-N(R^{1*}),~~
- (4) ~~O,~~
- (5) ~~S,~~

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (6) SO_2 ,
- (7) SO_2 ,
- (8) $\text{C}(\text{R}^{2*}, \text{R}^{3*})$, and
- (9) 

wherein R^{1*} , R^{2*} , and R^{3*} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (c) substituted or unsubstituted $\text{C}_2\text{--C}_6$ alkenyl,
- (d) substituted or unsubstituted $\text{C}_2\text{--C}_6$ alkynyl,
- (e) substituted or unsubstituted aryl,
- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R_1 is selected from the group consisting of

- (1) H,
- (2) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (3) COOH ,
- (4) halo,
- (5) OR^{1t} , and
- (6) NHR^{1t} ,


wherein R^{1t} is H or $\text{C}_1\text{--C}_6$ alkyl;

R_2 is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and
- (3) substituted or unsubstituted heterocyclyl; and

W is selected from the group consisting of

- (1) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (2) $\text{N}(\text{R}^{1w}, \text{R}^{2w})$, and



wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted C_1-C_6 alkyl,
- (c) substituted or unsubstituted aryl,
- (d) substituted or unsubstituted heterocyclyl, and
- (e) substituted or unsubstituted heteroaryl, wherein R^{1w} and R^{2w} are not both H ;

Z is selected from the group consisting of

- (a) O ,
- (b) NR^z ,
- (c) S ,
- (d) SO ,
- (e) SO_2 , and
- (f) CH_2 ,

wherein R^z is H or substituted or unsubstituted alkyl group; and

R^{4w} is selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted C_1-C_6 alkyl,
- (c) $COOR^{5w}$,
- (d) $CONH_2$,
- (e) OR^{5w} , and
- (f) NHR^{5w} ,


wherein R^{5w} is H or C_1-C_6 alkyl; and

r is 0, 1, or 2.

24. (Original) The composition of Claim 23 further comprising at least one additional agent for the treatment of cancer.

25. (Original) The composition of Claim 24, wherein the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, gleevec, herceptin, 5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.

26. (Currently amended) A method for treating a condition by modulation of phosphatidylinositol (PI) 3-kinase activity comprising administering to a human or animal subject in need of such treatment an effective amount of a compound ~~having the formula I of Claim 1.~~



~~or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof,~~
~~wherein~~

~~Y is selected from the group consisting of~~

- ~~(1) substituted or unsubstituted C₁-C₆-alkyl,~~
- ~~(2) substituted or unsubstituted C₂-C₆-alkenyl,~~
- ~~(3) substituted or unsubstituted C₂-C₆-alkynyl,~~
- ~~(4) substituted or unsubstituted aryl,~~
- ~~(5) substituted or unsubstituted heterocyclyl, and~~
- ~~(6) substituted or unsubstituted heteroaryl;~~

~~X is selected from the group consisting of~~

- ~~(1) a direct link,~~
- ~~(2) N(R^{1*}),~~

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

(3) $(\text{CH}_2)_m \text{C}(\text{R}^{2*}, \text{R}^{3*}) \text{N}(\text{R}^{1*})$,


(4) O ,

(5) S ,

(6) SO ,

(7) SO_2 ,

(8) $\text{C}(\text{R}^{2*}, \text{R}^{3*})$, and



(9) -- ,

wherein R^{1*} , R^{2*} , and R^{3*} are selected from the group consisting of

(a) H ,

(b) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,

(c) substituted or unsubstituted $\text{C}_2\text{--C}_6$ alkenyl,

(d) substituted or unsubstituted $\text{C}_2\text{--C}_6$ alkynyl,

(e) substituted or unsubstituted aryl,

(f) substituted or unsubstituted heterocyclyl,

(g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R_1 is selected from the group consisting of

(1) H ,

(2) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,

(3) COOH ,

(4) halo,

(5) OR^{1t} , and

(6) NHR^{1t} ,

wherein R^{1t} is H or $\text{C}_1\text{--C}_6$ alkyl;

R_2 is selected from the group consisting of

(1) substituted or unsubstituted aryl,

(2) substituted or unsubstituted heteroaryl, and


(3) substituted or unsubstituted heterocyclyl; and

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

W is selected from the group consisting of

(1) substituted or unsubstituted C_1-C_6 -alkyl,

(2) $N(R^{1w}, R^{2w})$, and



wherein R^{1w} and R^{2w} are selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6 -alkyl,

(c) substituted or unsubstituted aryl,

(d) substituted or unsubstituted heterocyclyl, and

(e) substituted or unsubstituted heteroaryl, wherein R^{1w} and R^{2w} are not both H;

Z is selected from the group consisting of

(a) O,

(b) NR^z ,

(c) S,

(d) SO,

(e) SO_2 , and

(f) CH_2 ,

wherein R^z is H or substituted or unsubstituted alkyl group; and

R^{4w} is selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6 -alkyl,

(c) $COOR^{5w}$,

(d) $CONH_2$,

(e) OR^{5w} , and

(f) NHR^{5w} ,


wherein R^{5w} is H or C_1-C_6 -alkyl; and

r is 0, 1, or 2.

27. (Original) The method of Claim 26, wherein the compound has an IC₅₀ value of less than about 20 μ M in a cell proliferation assay.

28. (Original) The method of Claim 26, wherein the condition is cancer.

29. (Currently amended) A method for inhibiting phosphatidylinositol (PI) 3-kinase activity in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of Claim 1 effective to inhibit phosphatidylinositol (PI) 3-kinase activity in the human or animal subject, wherein the compound has the formula I:



(I)

~~or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof,~~
~~wherein~~


Y is selected from the group consisting of

- (1) substituted or unsubstituted C₁-C₆-alkyl,
- (2) substituted or unsubstituted C₂-C₆-alkenyl,
- (3) substituted or unsubstituted C₂-C₆-alkynyl,
- (4) substituted or unsubstituted aryl,
- (5) substituted or unsubstituted heterocyclyl, and
- (6) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) N(R^{1*}),
- (3) (CH₂)_m C(R^{2*}, R^{3*}) N(R^{1*}),
- (4) O,

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (5) S ,
- (6) SO ,
- (7) SO_2 ,
- (8) $\text{C}(\text{R}^{2*}, \text{R}^{3*})$, and
- (9) 

wherein R^{1*} , R^{2*} , and R^{3*} are selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (c) substituted or unsubstituted $\text{C}_2\text{--C}_6$ alkenyl,
- (d) substituted or unsubstituted $\text{C}_2\text{--C}_6$ alkynyl,
- (e) substituted or unsubstituted aryl,
- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R_1 is selected from the group consisting of

- (1) H ,
- (2) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (3) COOH ,
- (4) halo,
- (5) OR^{1t} , and
- (6) NHR^{1t} ,

wherein R^{1t} is H or $\text{C}_1\text{--C}_6$ alkyl;


R_2 is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and
- (3) substituted or unsubstituted heterocyclyl; and

W is selected from the group consisting of

- (1) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,

(2) $\text{N}(\text{R}^{1w}, \text{R}^{2w})$, and



(3) $\text{Z}(\text{CH}_2)^r$;

wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (c) substituted or unsubstituted aryl,
- (d) substituted or unsubstituted heterocyclyl, and
- (e) substituted or unsubstituted heteroaryl, wherein R^{1w} and R^{2w} are not both H ;

Z is selected from the group consisting of

- (a) O ,
- (b) NR^z ,
- (c) S ,
- (d) SO ,
- (e) SO_2 , and
- (f) CH_2 ,

wherein R^z is H or substituted or unsubstituted alkyl group; and


R^{4w} is selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted $\text{C}_1\text{--C}_6$ alkyl,
- (c) COOR^{5w} ,
- (d) CONH_2 ,
- (e) OR^{5w} , and
- (f) NHR^{5w} ,

wherein R^{5w} is H or $\text{C}_1\text{--C}_6$ alkyl; and

r is 0, 1, or 2.

30. (Currently amended) A method for treating a cancer disorder in a human or animal subject, comprising administering to the human or animal subject a composition comprising an amount of a compound of Claim 1 effective to inhibit phosphatidylinositol (PI) 3-kinase activity in the human or animal subject, ~~wherein the compound has the formula I:~~



(I)

~~or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof,~~
~~wherein~~


~~Y is selected from the group consisting of~~

- (1) ~~substituted or unsubstituted C₁-C₆ alkyl,~~
- (2) ~~substituted or unsubstituted C₂-C₆ alkenyl,~~
- (3) ~~substituted or unsubstituted C₂-C₆ alkynyl,~~
- (4) ~~substituted or unsubstituted aryl,~~
- (5) ~~substituted or unsubstituted heterocyclyl, and~~
- (6) ~~substituted or unsubstituted heteroaryl;~~

~~X is selected from the group consisting of~~

- (1) ~~a direct link,~~
- (2) ~~N(R^{1*}),~~
- (3) ~~(CH₂)_m-C(R^{2*},R^{3*})-N(R^{1*}),~~
- (4) ~~O,~~
- (5) ~~S,~~
- (6) ~~SO,~~
- (7) ~~SO₂,~~
- (8) ~~C(R^{2*},R^{3*}), and~~

LAW OFFICES OF
CHRISTENSEN OCONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



wherein R^{1*} , R^{2*} , and R^{3*} are selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted C_1-C_6 -alkyl,
- (c) substituted or unsubstituted C_2-C_6 -alkenyl,
- (d) substituted or unsubstituted C_2-C_6 -alkynyl,
- (e) substituted or unsubstituted aryl,
- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R_1 is selected from the group consisting of

- (1) H ,
- (2) substituted or unsubstituted C_1-C_6 -alkyl,
- (3) $COOH$,
- (4) halo,
- (5) OR^{1t} , and
- (6) NHR^{1t} ,


wherein R^{1t} is H or C_1-C_6 -alkyl;

R_2 is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and
- (3) substituted or unsubstituted heterocyclyl; and

W is selected from the group consisting of

- (1) substituted or unsubstituted C_1-C_6 -alkyl,
- (2) $N(R^{1w}, R^{2w})$, and



LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted C_1-C_6 alkyl,
- (c) substituted or unsubstituted aryl,
- (d) substituted or unsubstituted heterocyclyl, and
- (e) substituted or unsubstituted heteroaryl, wherein R^{1w} and R^{2w} are not both H ;

Z is selected from the group consisting of

- (a) O ,
- (b) NR^z ,
- (c) S ,
- (d) SO ,
- (e) SO_2 , and
- (f) CH_2 ,

wherein R^z is H or substituted or unsubstituted alkyl group; and

R^{4w} is selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted C_1-C_6 alkyl,
- (c) $COOR^{5w}$,
- (d) $CONH_2$,
- (e) OR^{5w} , and
- (f) NHR^{5w} ,

wherein R^{5w} is H or C_1-C_6 alkyl; and

r is 0, 1, or 2.


31. (Original) The method of Claim 30 further comprising administering to the human or animal subject at least one additional agent for the treatment of cancer.

32. (Original) The method of Claim 31, wherein the at least one additional agent for the treatment of cancer is selected from irinotecan, topotecan, gemcitabine, gleevec, herceptin,

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

5-fluorouracil, leucovorin, carboplatin, cisplatin, taxanes, tezacitabine, cyclophosphamide, vinca alkaloids, imatinib, anthracyclines, rituximab, tamoxifen, CPT 11, and trastuzumab.

33. (Currently amended) A method for inhibiting tumor growth in a human or animal subject, comprising administering to the human or animal subject in need thereof an effective amount of a compound having the formula I: Claim 1.



(I)

~~or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof,~~
wherein


Y is selected from the group consisting of

- (1) substituted or unsubstituted C₁-C₆-alkyl,
- (2) substituted or unsubstituted C₂-C₆-alkenyl,
- (3) substituted or unsubstituted C₂-C₆-alkynyl,
- (4) substituted or unsubstituted aryl,
- (5) substituted or unsubstituted heterocyclyl, and
- (6) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) N(R^{1*}),
- (3) (CH₂)_m-C(R^{2*}, R^{3*})N(R^{1*}),
- (4) O,
- (5) S,
- (6) SO,
- (7) SO₂,
- (8) C(R^{2*}, R^{3*}), and

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



wherein R^{1x} , R^{2x} , and R^{3x} are selected from the group consisting of

- (a) H ,
- (b) substituted or unsubstituted C_1-C_6 alkyl,
- (c) substituted or unsubstituted C_2-C_6 alkenyl,
- (d) substituted or unsubstituted C_2-C_6 alkynyl,
- (e) substituted or unsubstituted aryl,
- (f) substituted or unsubstituted heterocyclyl,
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R_1 is selected from the group consisting of

- (1) H ,
- (2) substituted or unsubstituted C_1-C_6 alkyl,
- (3) $COOH$,
- (4) halo,
- (5) OR^{1t} , and
- (6) NHR^{1t} ,

wherein R^{1t} is H or C_1-C_6 alkyl;


R_2 is selected from the group consisting of

- (1) substituted or unsubstituted aryl,
- (2) substituted or unsubstituted heteroaryl, and
- (3) substituted or unsubstituted heterocyclyl; and

W is selected from the group consisting of

- (1) substituted or unsubstituted C_1-C_6 alkyl,

- (2) $N(R^{1w}, R^{2w})$, and



LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) —H,
- (b) —substituted or unsubstituted C₁—C₆ alkyl,
- (c) —substituted or unsubstituted aryl,
- (d) —substituted or unsubstituted heterocyclyl, and
- (e) —substituted or unsubstituted heteroaryl, wherein R^{1w} and R^{2w} are not both H;

Z is selected from the group consisting of

- (a) —O—,
- (b) —NR^z—,
- (c) —S—,
- (d) —SO—,
- (e) —SO₂—, and
- (f) —CH₂—,

wherein R^z is H or substituted or unsubstituted alkyl group; and

R^{4w} is selected from the group consisting of


- (a) —H,
- (b) —substituted or unsubstituted C₁—C₆ alkyl,
- (c) —COOR^{5w},
- (d) —CONH₂,
- (e) —OR^{5w}, and
- (f) —NHR^{5w},

wherein R^{5w} is H or C₁—C₆ alkyl; and

r is 0, 1, or 2.

34. (Currently amended) A method for inhibiting the proliferation of capillaries in a human or animal subject, comprising administering to the human or animal subject in need thereof an effective amount of a compound having the formula I of Claim 1.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



(I)

or a stereoisomer, tautomer, pharmaceutically acceptable salt, ester, or prodrug thereof,
wherein

Y is selected from the group consisting of

- (1) substituted or unsubstituted C₁-C₆-alkyl,
- (2) substituted or unsubstituted C₂-C₆-alkenyl,
- (3) substituted or unsubstituted C₂-C₆-alkynyl,
- (4) substituted or unsubstituted aryl,
- (5) substituted or unsubstituted heterocyclyl, and
- (6) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

- (1) a direct link,
- (2) N(R^{1*}),
- (3) (CH₂)_m C(R^{2*}, R^{3*}) N(R^{1*}),
- (4) O,
- (5) S,
- (6) SO,
- (7) SO₂,
- (8) C(R^{2*}, R^{3*}), and
- (9) ,

wherein R^{1*}, R^{2*}, and R^{3*} are selected from the group consisting of

- (a) H,
- (b) substituted or unsubstituted C₁-C₆-alkyl,
- (c) substituted or unsubstituted C₂-C₆-alkenyl,

LAW OFFICES OF
CHRISTENSEN OCONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- (d) substituted or unsubstituted C_2-C_6 alkynyl;
- (e) substituted or unsubstituted aryl;
- (f) substituted or unsubstituted heterocyclyl;
- (g) substituted or unsubstituted heteroaryl; and

m is 0, 1, 2, 3, or 4;

R_1 is selected from the group consisting of

- (1) H;
- (2) substituted or unsubstituted C_1-C_6 alkyl;
- (3) COOH;
- (4) halo;
- (5) OR^{1t} , and
- (6) NHR^{1t} ,

wherein R^{1t} is H or C_1-C_6 alkyl;

R_2 is selected from the group consisting of

- (1) substituted or unsubstituted aryl;
- (2) substituted or unsubstituted heteroaryl, and
- (3) substituted or unsubstituted heterocyclyl; and

W is selected from the group consisting of

- (1) substituted or unsubstituted C_1-C_6 alkyl;
- (2) $N(R^{1w}, R^{2w})$, and
- (3) $\begin{array}{c} | \\ R^{4w} - C - N \\ | \\ \backslash \quad / \\ Z \quad (CH_2)^r \end{array}$;

wherein R^{1w} and R^{2w} are selected from the group consisting of

- (a) H;
- (b) substituted or unsubstituted C_1-C_6 alkyl;
- (c) substituted or unsubstituted aryl;
- (d) substituted or unsubstituted heterocyclyl, and

(e) ~~substituted or unsubstituted heteroaryl, wherein R^{4w} and R^{2w} are not both H;~~

~~Z is selected from the group consisting of~~

- (a) ~~O,~~
- (b) ~~NR^{2z},~~
- (c) ~~S,~~
- (d) ~~SO,~~
- (e) ~~SO₂, and~~
- (f) ~~CH₂,~~

~~wherein R^{2z} is H or substituted or unsubstituted alkyl group; and~~

~~R^{4w} is selected from the group consisting of~~

- (a) ~~H,~~
- (b) ~~substituted or unsubstituted C₁-C₆ alkyl,~~
- (c) ~~COOR^{5w},~~
- (d) ~~CONH₂,~~
- (e) ~~OR^{5w}, and~~
- (f) ~~NHR^{5w},~~


~~wherein R^{5w} is H or C₁-C₆ alkyl; and~~

~~r is 0, 1, or 2.~~

35. (Canceled)
34. (Canceled) Redundant Claim. Same as Claim 34.
36. (Canceled)
37. (New) A compound of Claim 1, wherein R₂ is hydroxy-substituted phenyl.
38. (New) A compound of Claim 1, wherein R₂ is substituted or unsubstituted pyridinyl.
39. (New) A compound of Claim 1, wherein R₂ is substituted or unsubstituted pyrimidinyl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

40. (New) A compound of Claim 1, wherein W is



41. (New) A compound of Claim 40, wherein R^{4w} is H, r is 1, and Z is O.

42. (New) A compound of Claim 1, wherein Y is substituted or unsubstituted heterocyclyl.

43. (New) A compound of Claim 1, wherein X is a O and Y is substituted or unsubstituted heterocyclyl.

44. (New) A compound of Claim 1, wherein X is a direct link and Y is substituted or unsubstituted heterocyclyl.

45. (New) A compound of Claim 40, wherein R^{4w} is H, r is 1, Z is O, Y is substituted or unsubstituted heterocyclyl, R₁ is H, and R₂ is substituted or unsubstituted heteroaryl.

46. (New) A compound of Claim 40, wherein R^{4w} is H, r is 1, Z is O, X is O or a direct link, Y is substituted or unsubstituted heterocyclyl, R₁ is H, and R₂ is substituted or unsubstituted heteroaryl.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100